ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences

Core Insights - ImmunityBio, Inc. (NASDAQ:IBRX) has shown significant stock performance, rising 10.80% to $2.36, reflecting broader market optimism and positioning ahead of a global health conference [1][3] - The company will participate in the 37th Piper Sandler Annual Healthcare Conference in New York from December 2 to 4, where investors will be keen on updates regarding its clinical pipelines [2][3] - ImmunityBio reported a 21.6% reduction in net loss attributable to shareholders, narrowing it to $67.25 million from $85.73 million year-on-year, attributed to increased product revenues and lower interest expenses [3] - Revenues surged by 425% to $32.06 million from $6.1 million year-on-year, driven by strong sales of its NMIBC treatment, Anktiva [3]